Tyler Lopez,Aaron Ramirez,Chris Benitez et al.
Tyler Lopez et al.
Background: Proteases are one of the largest pharmaceutical targets for drug developments. Their dysregulations result in a wide variety of diseases. Because proteolytic networks usually consist of protease family members that share high st...
Ying Fu,Mitchell Ho
Ying Fu
Currently, four antibody-drug conjugates (ADCs) are approved by the Food and Drug Administration or the European Medicine Agency to treat cancer patients. More than 60 ADCs are in clinical development for cancer therapy. More than 60% of AD...
Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma [0.03%]
针对多发性骨髓瘤靶向B细胞成熟抗原的免疫毒素的临床前开发
Zoe Shancer,Matthew Williams,Austin Igelman et al.
Zoe Shancer et al.
Background: Multiple myeloma (MM) is a B-cell malignancy that is incurable for the majority of patients. New treatments are urgently needed. Recombinant immunotoxins (RITs) are chimeric proteins that are composed of the F...
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers [0.03%]
曲妥珠单抗引起的心脏毒性：目前的认识、挑战与前景
Nishant Mohan,Jiangsong Jiang,Milos Dokmanovic et al.
Nishant Mohan et al.
Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associate...
Mitchell Ho
Mitchell Ho
Single domain antibodies have emerged as a new class of therapeutic molecules in antibody engineering. A single domain antibody (shark VNAR), in contrast to a conventional antibody (Fv), is capable of binding a buried functional site consis...